T-Cell Therapy : Options for Infectious Diseases
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America..
The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61Suppl 3 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 61Suppl 3(2015) vom: 15. Okt., Seite S217-24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parida, Shreemanta K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adoptive cell therapy |
|---|
| Anmerkungen: |
Date Completed 11.07.2016 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/civ615 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM253126649 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM253126649 | ||
| 003 | DE-627 | ||
| 005 | 20231224165549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/civ615 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0843.xml |
| 035 | |a (DE-627)NLM253126649 | ||
| 035 | |a (NLM)26409284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parida, Shreemanta K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-Cell Therapy |b Options for Infectious Diseases |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. | ||
| 520 | |a The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR | |
| 650 | 4 | |a Mtb | |
| 650 | 4 | |a T-cells | |
| 650 | 4 | |a adoptive cell therapy | |
| 650 | 4 | |a host-directed therapy | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 700 | 1 | |a Poiret, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Zhenjiang, Liu |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Qingda |e verfasserin |4 aut | |
| 700 | 1 | |a Heyckendorf, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Ambati, Aditya S |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Martin V |e verfasserin |4 aut | |
| 700 | 1 | |a Valentini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Rangelova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Dodoo, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 61Suppl 3(2015) vom: 15. Okt., Seite S217-24 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:61Suppl 3 |g year:2015 |g day:15 |g month:10 |g pages:S217-24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/civ615 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61Suppl 3 |j 2015 |b 15 |c 10 |h S217-24 | ||